Retinal Vascular Changes in Patients After Coronavirus Disease 2019 (COVID-19)

Sponsor
University Hospital Olomouc (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT05747547
Collaborator
Palacky University (Other)
30
1
14
2.1

Study Details

Study Description

Brief Summary

The study examines changes in retinal oximetry in patients after COVID-19 disease. It aims to analyze and quantify possible retinal microvascular abnormalities that may result from possible post-inflammatory damage to the endothelium of the vessels associated with COVID-19 disease. Retinal vascular involvement may indicate similar changes in the vascular system in other organs.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Central visual acuity
  • Diagnostic Test: Intraocular pressure measurement
  • Diagnostic Test: Slit lamp examination
  • Diagnostic Test: Retinal oximetry
  • Diagnostic Test: Optical coherence tomography and angiography

Detailed Description

The retinal blood vessels are the only blood vessels in the body that can be observed directly. Patients with COVID-19 pneumonia have been shown to have reduced macular vessel density in the foveal region. As a result, some layers of the retina atrophy, reducing oxygen consumption by the retina. Based on this, it is expected that patients after COVID-19 pneumonia, or after a more severe course of the disease, will have normal arterial retinal oxygen saturation but higher venous retinal oxygen saturation and lower arterio-venous difference than patients after mild disease.

Study Design

Study Type:
Observational
Anticipated Enrollment :
30 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Retinal Vascular Changes in Patients After Coronavirus Disease 2019 (COVID-19) Based on Retinal Oximetry
Actual Study Start Date :
Aug 1, 2022
Anticipated Primary Completion Date :
May 1, 2023
Anticipated Study Completion Date :
Oct 1, 2023

Arms and Interventions

Arm Intervention/Treatment
mild disease

asymptomatic or paucisymptomatic patients with laboratory-confirmed severe acute respiratory syndrome coronavirus 2 infection (SARS-CoV2-infection) who received outpatient care

Diagnostic Test: Central visual acuity
Measurement of central visual acuity using ETDRS (Early Treatment Diabetic Retinopathy Study) optotypes or Snellen optotype chart.

Diagnostic Test: Intraocular pressure measurement
Measurement of intraocular pressure using non-contact Canon TX-20P tonometer.

Diagnostic Test: Slit lamp examination
Slit lamp examination of the anterior and posterior segment of the eye after pharmacological dilation of the pupil using application of short-time mydriatics (1% tropicamide and 10% phenylephrine).

Diagnostic Test: Retinal oximetry
Performing of retinal oximetry with an Oxymap T1 instrument (Oxymap ehf.) paired with a Topcon TRC-50DX retinal camera.

Diagnostic Test: Optical coherence tomography and angiography
Performing of optical coherence tomography and angiography with the Spectralis Optical Coherence Tomography Plus (Heidelberg Engineering).

moderate disease

patients with laboratory-confirmed SARS-CoV2-infection and radiology-confirmed pneumonia who did not require extracorporeal membrane oxygenation

Diagnostic Test: Central visual acuity
Measurement of central visual acuity using ETDRS (Early Treatment Diabetic Retinopathy Study) optotypes or Snellen optotype chart.

Diagnostic Test: Intraocular pressure measurement
Measurement of intraocular pressure using non-contact Canon TX-20P tonometer.

Diagnostic Test: Slit lamp examination
Slit lamp examination of the anterior and posterior segment of the eye after pharmacological dilation of the pupil using application of short-time mydriatics (1% tropicamide and 10% phenylephrine).

Diagnostic Test: Retinal oximetry
Performing of retinal oximetry with an Oxymap T1 instrument (Oxymap ehf.) paired with a Topcon TRC-50DX retinal camera.

Diagnostic Test: Optical coherence tomography and angiography
Performing of optical coherence tomography and angiography with the Spectralis Optical Coherence Tomography Plus (Heidelberg Engineering).

severe disease

patients with laboratory-confirmed SARS-CoV2-infection and acute respiratory distress syndrome who required extracorporeal membrane oxygenation

Diagnostic Test: Central visual acuity
Measurement of central visual acuity using ETDRS (Early Treatment Diabetic Retinopathy Study) optotypes or Snellen optotype chart.

Diagnostic Test: Intraocular pressure measurement
Measurement of intraocular pressure using non-contact Canon TX-20P tonometer.

Diagnostic Test: Slit lamp examination
Slit lamp examination of the anterior and posterior segment of the eye after pharmacological dilation of the pupil using application of short-time mydriatics (1% tropicamide and 10% phenylephrine).

Diagnostic Test: Retinal oximetry
Performing of retinal oximetry with an Oxymap T1 instrument (Oxymap ehf.) paired with a Topcon TRC-50DX retinal camera.

Diagnostic Test: Optical coherence tomography and angiography
Performing of optical coherence tomography and angiography with the Spectralis Optical Coherence Tomography Plus (Heidelberg Engineering).

Outcome Measures

Primary Outcome Measures

  1. Successful performing of retinal oximetry images in 90% of enrolled patients. [3 months]

    90% of captured fundus images of retinal oximetry are useful for subsequent analysis.

  2. Successful analysis of retinal oxygen saturation in 90% of enrolled patients. [3 months]

    The parameters analyzed by retinal oximetry are arterial retinal oxygen saturation (%), venous retinal oxygen saturation (%), arterio-venous difference (%), arteriolar and venular diameter (µm).

Secondary Outcome Measures

  1. Successful performing of optical coherence tomography and angiography in 90% of enrolled patients. [3 months]

    90% of captured images of optical coherence tomography and angiography are useful for subsequent analysis.

  2. Successful analysis of optical coherence tomography in 90% of enrolled patients. [3 months]

    The parameters analyzed by optical coherence tomography are central retinal thickness (µm), ganglion cell layer thickness (µm), retinal nerve fiber layer thickness (µm), choroid thickness (µm) in the macular region and optic nerve head retinal nerve fiber layer thickness (µm).

  3. Successful analysis of optical coherence tomography angiography in 90% of enrolled patients. [3 months]

    The parameter analyzed by optical coherence tomography angiography is the size of foveal avascular zone (µm2).

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • age over 18 years

  • history of laboratory-confirmed SARS-CoV2-infection

  • transparent ocular media allowing for fundus photography

  • signed informed consent

Exclusion Criteria:
  • known eye disease that has been shown to affect retinal oxygen saturation (diabetic retinopathy, vascular occlusions, use of antiglaucoma drugs)

  • any other serious eye disease (advanced or decompensated glaucoma, retinitis pigmentosa, age-related macular degeneration, ocular tumors)

  • reduced transparency of the ocular media limiting the visualization of the ocular background and preventing a good quality image from being taken (severe dry eye syndrome, corneal scarring, cataract, significant vitreous haze, vitreous hemorrhage)

  • significant refractive error not allowing for sharpening of imaging examinations

  • previous intraocular surgery except cataract surgery if performed more than 3 months before the examination

  • previous intravitreal application of anti-vascular endothelial growth factor therapy or laser photocoagulation of the retina

  • previous severe eye injury

  • acute eye infection

  • known systemic disease affecting retinal oxygen saturation or causing changes in the ocular background (chronic obstructive pulmonary disease, multiple myeloma, malignant hypertension, hyperglobulinemia)

  • pregnancy, breastfeeding

Contacts and Locations

Locations

Site City State Country Postal Code
1 Department of Ophthalmology, University Hospital Olomouc Olomouc Czechia

Sponsors and Collaborators

  • University Hospital Olomouc
  • Palacky University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Zuzana Schreiberova, Principal Investigator, University Hospital Olomouc
ClinicalTrials.gov Identifier:
NCT05747547
Other Study ID Numbers:
  • 9/23
First Posted:
Feb 28, 2023
Last Update Posted:
Feb 28, 2023
Last Verified:
Feb 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 28, 2023